Publication Dr.Vip

List of all international publications by Dr. Vip Viprakasit (2005-2017)

  1. Viprakasit V. Iron chelation in hemoglobinopathies: Update on hemoglobinopathies. Hematology Education: the education programme for the annual congress of the European Hematology Association (EHA); 2017; in press.
  2. Krittayaphong R, Viprakasit V, Saiviroonporn P, Wood JC. Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassemia patient real-world practice: A multicenter study. Br J Haematol. 2017 April 12. [Epub ahead of print]
  3. Saliba AN, Musallam KM, Cappellini MD, Graziadei G, Daar S, Viprakasit V, et al. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. Am J Hematol. 2017;92(3):E35-e7.
  4. Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, et al. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol. 2017;176(2):288-99.
  5. Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug design, development and therapy. 2016;10:4073-8.
  6. Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016;57:23-9.
  7. Porter JB, El-Alfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016;96(1):19-26.
  8. Jiang Z, Luo HY, Huang S, Farrell JJ, Davis L, Theberge R, et al. The genetic basis of asymptomatic codon 8 frame-shift (HBB:c25_26delAA) beta(0) -thalassaemia homozygotes. Br J Haematol. 2016;172(6):958-65.
  9. Foong WC, Ho JJ, Loh CK, Viprakasit V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. The Cochrane database of systematic reviews. 2016;10:Cd011579.
  10. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Dohner H, et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101(2):115-208.
  11. Cappellini MD, Porter JB, Musallam KM, Kattamis A, Viprakasit V, Galanello R, et al. Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European journal of internal medicine. 2016;28:91-6.
  12. Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox sanguinis. 2015;108(1):1-10.
  13. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol. 2015;168(2):284-90.
  14. Saiviroonporn P, Viprakasit V, Krittayaphong R. Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme. BMC medical imaging. 2015;15:52.
  15. Rujanapun N, Aueviriyavit S, Boonrungsiman S, Rosena A, Phummiratch D, Riolueang S, et al. Human primary erythroid cells as a more sensitive alternative in vitro hematological model for nanotoxicity studies: Toxicological effects of silver nanoparticles. Toxicology in vitro : an international journal published in association with BIBRA. 2015;29(8):1982-92.
  16. Phuakpet K, Sanpakit K, Vathana N, Takpradit C, Chokephaibulkit K, Viprakasit V. Hemophagocytic lymphohistiocytosis following dengue hemorrhagic fever in Hb H/Hb Constant Spring patient. Pediatrics international : official journal of the Japan Pediatric Society. 2015;57(4):763-5.
  17. Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinc Y, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015;95(3):244-53.
  18. Viprakasit V. α-thalassaemia: a genotype-phenotype correlation and management. ISBT Science Series; 2015: 10(Suppl. 1): 295-304.
  19. Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, et al. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;125(25):3868-77.
  20. Viprakasit V, Tyan P, Rodmai S, Taher AT. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet journal of rare diseases. 2014;9:131.
  21. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) 3rd edition. Nicosia (CY): Thalassaemia International Federation; 2014.
  22. Viprakasit V, Ekwattanakit S, Riolueang S, Chalaow N, Fisher C, Lower K, et al. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood. 2014;123(10):1586-95.
  23. Viprakasit V, Ekwattanakit S, Chalaow N, Riolueang S, Wijit S, Tanyut P, et al. Clinical presentation and molecular identification of four uncommon alpha globin variants in Thailand. Initiation codon mutation of alpha2-globin Gene (HBA2:c.1delA), donor splice site mutation of alpha1-globin gene (IVSI-1, HBA1:c.95 + 1G>A), hemoglobin Queens Park/Chao Pra Ya (HBA1:c.98T>A) and hemoglobin Westmead (HBA2:c.369C>G). Acta haematologica. 2014;131(2):88-94.
  24. Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, et al. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin. 2014;38(5):345-50.
  25. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol. 2014;92(6):521-6.
  26. Cappellin MDi, Viprakasit V, Taher A. An overview of current treatment strategies for β-thalassemia. Expert Opinion on Orphan Drug 2014; 2 (7): 665-679.
  27. Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo. Blood Cells Mol Dis. 2014;52(2-3):88-90.
  28. Sanpakit K, Viprakasit V. Variable genotype-phenotype correlations in patients with a rare nondeletional alpha-thalassemia; Hb Pak Num Po (HBA1: c.396_397insT). Journal of pediatric hematology/oncology. 2014;36(3):e185-9.
  29. Pongtanakul B, Sanpakit K, Chongkolwatana V, Viprakasit V. Normal cognitive functioning in a patient with Hb Bart’s hydrops successfully cured by hematopoietic SCT. Bone marrow transplantation. 2014;49(1):155-6.
  30. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood. 2014;123(10):1447-54.
  31. Viprakasit V, Rodmai S, Srichairatanakool S. Deferiprone for transfusional iron overload and its roles in developing countries. Expert Opinion on Orphan Drug 2014; in press. Expert Opinion on Orphan Drugs. 2014; 2 (2): 189-200.
  32. Nakavachara P, Pooliam J, Weerakulwattana L, Kiattisakthavee P, Chaichanwattanakul K, Manorompatarasarn R, et al. A normal reference of bone mineral density (BMD) measured by dual energy X-ray absorptiometry in healthy thai children and adolescents aged 5-18 years: a new reference for Southeast Asian Populations. PloS one. 2014;9(5):e97218.
  33. Jindatanmanusan P, Riolueang S, Glomglao W, Sukontharangsri Y, Chamnanvanakij S, Torcharus K, et al. Diagnostic applications of newborn screening for alpha-thalassaemias, haemoglobins E and H disorders using isoelectric focusing on dry blood spots. Annals of clinical biochemistry. 2014;51(Pt 2):237-47.
  34. Aydinok Y, Kattamis A, Viprakasit V. Current approach to iron chelation in children. Br J Haematol. 2014;165(6):745-55.
  35. Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, et al. Deferiprone (GPO-L-ONE((R)) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88(4):251-60.
  36. Viprakasit V, Limwongse C, Sukpanichnant S, Ruangvutilert P, Kanjanakorn C, Glomglao W, et al. Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand. Clinical chemistry and laboratory medicine. 2013;51(8):1605-14.
  37. Viprakasit V, Gattermann N, Lee JW, Porter JB, Taher AT, Habr D, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 2013;11(1):108-22.
  38. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409-15.
  39. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485-93.
  40. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol. 2013;88(6):503-6.
  41. Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. In: Weatherall D, editor. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). 1st edition. Nicosia (CY): Thalassaemia International Federation; 2013.
  42. Pongtanakul B, Viprakasit V. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood Cells Mol Dis. 2013;51(2):96-7.
  43. Nakavachara P, Viprakasit V. Adrenal insufficiency is prevalent in HbE/beta-thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement. Clinical endocrinology. 2013;79(6):776-83.
  44. Nakavachara P, Viprakasit V. Children with hemoglobin E/beta-thalassemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: a study from Thailand. Pediatr Blood Cancer. 2013;60(10):1683-8.
  45. Viprakasit V. Alpha-thalassaemia: From Clinical and Molecular Diagnosis to Bedside Management. Hematology Education: the education programme for the annual congress of the European Hematology Association (EHA); 2013; 7(1); 329-338
  46. Chalaow N, Thein SL, Viprakasit V. The 12.6 kb-deletion in the beta-globin gene cluster is the known Thai/Vietnamese (deltabeta)0-thalassemia commonly found in Southeast Asia. Haematologica. 2013;98(9):e117-8.
  47. Tritipsombut J, Phylipsen M, Viprakasit V, Chalaow N, Sanchaisuriya K, Giordano PC, et al. A single-tube multiplex gap-polymerase chain reaction for the detection of eight beta-globin gene cluster deletions common in Southeast Asia. Hemoglobin. 2012;36(6):571-80.
  48. Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970-7.
  49. Steensma DP, Viprakasit V, Kyle RA, Shampo MA. Prince Wongsa Dhiraj Snid–Thai physician and diplomat. Mayo Clinic proceedings. 2012;87(11):e93.
  50. Saiviroonporn P, Viprakasit V, Sanpakit K, Wood JC, Krittayaphong R. Intersite validations of the pixel-wise method for liver R2* analysis in transfusion-dependent thalassemia patients: a more accessible and affordable diagnostic technology. Hematology/oncology and stem cell therapy. 2012;5(2):91-5.
  51. Saiviroonporn P, Viprakasit V, Maneesai A, Siritanaratkul N, Pongtanakul B, Wood JC, et al. Inter-site validations of the Pixel-Wise method for cardiac T2* analysis in transfusion-dependent Thai thalassemia patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2012;95 Suppl 2:S165-72.
  52. Phumeetham S, Chat-Uthai N, Manavathongchai M, Viprakasit V. Genetic association study of tumor necrosis factor-alpha with sepsis and septic shock in Thai pediatric patients. Jornal de pediatria. 2012;88(5):417-22.
  53. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica. 2012;97(6):842-8.
  54. Neufeld EJ, Galanello R, Viprakasit V, Aydinok Y, Piga A, Harmatz P, et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood. 2012;119(14):3263-8.
  55. Ekwattanakit S, Monteerarat Y, Riolueang S, Tachavanich K, Viprakasit V. Association of xmn I polymorphism and hemoglobin e haplotypes on postnatal gamma globin gene expression in homozygous hemoglobin e. Advances in hematology. 2012;2012:528075.
  56. Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, et al. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International journal of hematology. 2011;93(3):319-28.
  57. Saiviroonporn P, Viprakasit V, Boonyasirinant T, Khuhapinant A, Wood JC, Krittayaphong R. Comparison of the region-based and pixel-wise methods for cardiac T2* analysis in 50 transfusion-dependent Thai thalassemia patients. Journal of computer assisted tomography. 2011;35(3):375-81.
  58. Rienhoff HY, Jr., Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96(4):521-5.
  59. Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, et al. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011;87(4):338-48.
  60. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
  61. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-71.
  62. Nuinoon M, Makarasara W, Mushiroda T, Setianingsih I, Wahidiyat PA, Sripichai O, et al. A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Human genetics. 2010;127(3):303-14.
  63. Monteerarat Y, Suptawiwat O, Boonarkart C, Uiprasertkul M, Auewarakul P, Viprakasit V. Inhibition of H5N1 highly pathogenic influenza virus by suppressing a specific sialyltransferase. Archives of virology. 2010;155(6):889-93.
  64. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-54.
  65. Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D, Viprakasit V, et al. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell. 2010;143(3):367-78.
  66. Laosombat V, Viprakasit V, Dissaneevate S, Leetanaporn R, Chotsampancharoen T, Wongchanchailert M, et al. Natural history of Southeast Asian Ovalocytosis during the first 3 years of life. Blood Cells Mol Dis. 2010;45(1):29-32.
  67. Horby P, Sudoyo H, Viprakasit V, Fox A, Thai PQ, Yu H, et al. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? Epidemiology and infection. 2010;138(11):1550-8.
  68. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia research. 2010;34(9):1143-50.
  69. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-66.
  70. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asian perspectives. International journal of hematology. 2009;90(4):435-45.
  71. Tachavanich K, Viprakasit V, Pung-Amritt P, Veerakul G, Chansing K, Tanphaichitr VS. Development of a comprehensive red blood cell enzymopathy laboratory in Thailand: the study of normal activity in eight erythroenzymes in Thais. The Southeast Asian journal of tropical medicine and public health. 2009;40(2):317-26.
  72. Tachavanich K, Viprakasit V, Chinchang W, Glomglao W, Pung-Amritt P, Tanphaichitr VS. Clinical and hematological phenotype of homozygous hemoglobin E: revisit of a benign condition with hidden reproductive risk. The Southeast Asian journal of tropical medicine and public health. 2009;40(2):306-16.
  73. Tachavanich K, Tanphaichitr VS, Utto W, Viprakasit V. Rapid flow cytometric test using eosin-5-maleimide for diagnosis of red blood cell membrane disorders. The Southeast Asian journal of tropical medicine and public health. 2009;40(3):570-5.
  74. Lower KM, Hughes JR, De Gobbi M, Henderson S, Viprakasit V, Fisher C, et al. Adventitious changes in long-range gene expression caused by polymorphic structural variation and promoter competition. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(51):21771-6.
  75. Lok CY, Merryweather-Clarke AT, Viprakasit V, Chinthammitr Y, Srichairatanakool S, Limwongse C, et al. Iron overload in the Asian community. Blood. 2009;114(1):20-5.
  76. Laosombat V, Viprakasit V, Chotsampancharoen T, Wongchanchailert M, Khodchawan S, Chinchang W, et al. Clinical features and molecular analysis in Thai patients with HbH disease. Ann Hematol. 2009;88(12):1185-92.
  77. Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology American Society of Hematology Education Program. 2009:26-34.
  78. Pariyaprasert W, Pacharn P, Visitsunthorn N, Chokephaibulkit K, Sanpakit K, Viprakasit V, et al. Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor. Asian Pacific journal of allergy and immunology. 2008;26(1):71-5.
  79. Viprakasit V, Chinchang W. Two independent origins of Hb Dhonburi (Neapolis) [beta 126 (H4) Val–>Gly]: an electrophoretically silent hemoglobin variant. Clinica chimica acta; international journal of clinical chemistry. 2007;376(1-2):179-83.
  80. Sura T, Trachoo O, Viprakasit V, Vathesatogkit P, Tunteeratum A, Busabaratana M, et al. Hemoglobin H disease induced by the common SEA deletion and the rare hemoglobin Quong Sze in a Thai female: longitudinal clinical course, molecular characterization, and development of a PCR/RFLP-based detection method. Ann Hematol. 2007;86(9):659-63.
  81. Sura T, Busabaratana M, Youngcharoen S, Wisedpanichkij R, Viprakasit V, Trachoo O. Haemoglobin Hope in a northern Thai family: first identification of homozygous haemoglobin Hope associated with haemoglobin H disease. Eur J Haematol. 2007;79(3):251-4.
  82. Puehringer H, Najmabadi H, Law HY, Krugluger W, Viprakasit V, Pissard S, et al. Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common alpha-thalassemia point mutations and deletions. Clinical chemistry and laboratory medicine. 2007;45(5):605-10.
  83. Khositseth S, Sirikanerat A, Wongbenjarat K, Opastirakul S, Khoprasert S, Peuksungnern R, et al. Distal renal tubular acidosis associated with anion exchanger 1 mutations in children in Thailand. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2007;49(6):841-50.e1.
  84. Chinchang W, Viprakasit V. Further identification of Hb G-Coushatta [beta22(B4)Glu–>Ala (GAA–>GCA)] in Thailand by the polymerase chain reaction-single-strand conformation polymorphism technique and by amplification refractory mutation system-polymerase chain reaction. Hemoglobin. 2007;31(1):93-9.
  85. Viprakasit V, Harteveld CL, Ayyub H, Stanley JS, Giordano PC, Wood WG, et al. A novel deletion causing alpha thalassemia clarifies the importance of the major human alpha globin regulatory element. Blood. 2006;107(9):3811-2.
  86. Viprakasit V, Chinchang W, Chotimarat P. Hb Woodville, a rare alpha-globin variant, caused by codon 6 mutation of the alpha1 gene. Eur J Haematol. 2006;76(1):79-82.
  87. Pattaragarn A, Viprakasit V, Supavekin S, Sumboonnanonda A. Immune-mediated hemolytic anemia in pediatric renal transplantation. Pediatric transplantation. 2006;10(6):740-3.
  88. De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science (New York, NY). 2006;312(5777):1215-7.
  89. Wasant P, Viprakasit V, Srisomsap C, Liammongkolkul S, Ratanarak P, Sathienkijakanchai A, et al. Argininosuccinate synthetase deficiency: mutation analysis in 3 Thai patients. The Southeast Asian journal of tropical medicine and public health. 2005;36(3):757-61.
  90. Viprakasit V, Suwanthol L, Sangpraypan T, Glomglao W, Utto W, Veerakul G. Hematological parameters and red blood cell indices in healthy Thai children: a revision for 2005. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2005;88 Suppl 8:S188-96.
  91. Viprakasit V, Chinchang W, Suwanthol L, Tanphaichitr VS. Common origin of a rare beta-globin initiation codon mutation (ATG–>AGG) in Asians. Clinical and laboratory haematology. 2005;27(6):409-15.
  92. Viprakasit V, Chinchang W, Glomglao W, Tanphaichitr VS. A rare association of alphaO-thalassemia (–SEA) and an initiation codon mutation (ATG–>A-G) of the alpha2 gene causes Hb H disease in Thailand. Hemoglobin. 2005;29(3):235-40.
  93. Vathana N, Viprakasit V, Sanpakit K, Chinchang W, Veerakul G, Tanphaichitr V. Clinical phenotypes and molecular diagnosis in a hitherto interaction of Hb E/beta thalassemia syndrome (beta(E)/beta(-31), (A –>G)). Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2005;88 Suppl 8:S66-71.
  94. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood. 2005;105(10):4096-102.
  95. Premawardhena A, Fisher CA, Olivieri NF, de Silva S, Arambepola M, Perera W, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet (London, England). 2005;366(9495):1467-70.
  96. Pongtanakul B, Narkbunnam N, Veerakul G, Sanpakit K, Viprakasit V, Tanphaichitr VT, et al. Dengue hemorrhagic fever in patients with thalassemia. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2005;88 Suppl 8:S80-5.
  97. Laosombat V, Sattayasevana B, Janejindamai W, Viprakasit V, Shirakawa T, Nishiyama K, et al. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in the south of Thailand and identification of a novel variant (G6PD Songklanagarind). Blood Cells Mol Dis. 2005;34(2):191-6.
  98. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106(3):1092-7.
  99. Chinthammitr Y, Chinchang W, Ruchutrakool T, Viprakasit V. Identification of the novel signal peptide mutation, antithrombin-Siriraj causes type-I antithrombin deficiency in thai patients. Thrombosis and haemostasis. 2005;94(3):678-9.
  100. Chinchang W, Viprakasit V, Pung-Amritt P, Tanphaichitr VS, Yenchitsomanus PT. Molecular analysis of unknown beta-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with beta-thalassemias and beta-globin variants. Clinical biochemistry. 2005;38(11):987-96.